CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 No DAC & Ipamorelin Half-Life — Dosing Timing

Real Peptides Research TeamEditorial

Updated June 17, 20269 min read

54 WORDS

Short answer

Key takeaways

CJC-1295 no DAC has a 30-minute half-life with peak GH release at 15–20 minutes, designed to amplify natural pulse amplitude without sustained elevation.
Ipamorelin has a 2-hour half-life and extends GH elevation for 3–4 hours, creating synergy when co-administered with CJC-1295 no DAC.
Lyophilised peptides must be stored at −20°C before reconstitution; once mixed with bacteriostatic water, refrigerate at 2–8°C and use within 28 days.
Temperature excursions above 8°C cause irreversible peptide denaturation that neither appearance nor potency testing at home can detect.
Optimal dosing is 1–3 times daily, spaced at least 4–6 hours apart to respect the body's GH pulse refractory period.
Co-administration 30–60 minutes before sleep or immediately post-training aligns with endogenous GH secretion patterns for maximum synergy.

The biggest reconstitution mistake researchers make with CJC-1295 no DAC isn't the mixing ratio. It's expecting it to behave like its DAC-modified counterpart. CJC-1295 no DAC (also called Modified GRF 1-29) has a plasma half-life of approximately 30 minutes, while ipamorelin stays active for roughly 2 hours. That narrow window isn't a design flaw. It's the mechanism that makes this combination so effective at amplifying natural growth hormone pulses without suppressing endogenous production the way longer-acting analogues can.

We've worked with research teams across cellular metabolism and peptide stability studies for years. The gap between protocols that work and those that waste expensive compounds comes down to three things most mixing guides never mention: precise reconstitution timing, temperature-controlled storage post-mixing, and dosing intervals that respect physiological GH pulse architecture.

What's the half-life of CJC-1295 no DAC and ipamorelin?

CJC-1295 no DAC (Modified GRF 1-29) has a plasma half-life of approximately 30 minutes, meaning peak growth hormone release occurs within 15–20 minutes of administration and returns to baseline within 90–120 minutes. Ipamorelin has a half-life of roughly 2 hours, with measurable GH elevation sustained for 3–4 hours post-injection. These short durations allow for multiple daily dosing without desensitising somatotroph cells or suppressing endogenous pulsatile secretion.

Here's what the basic answer misses: those half-lives don't exist in isolation. They're designed to synergise. CJC-1295 no DAC amplifies the amplitude of each GH pulse (how high the spike goes), while ipamorelin extends pulse duration (how long it stays elevated). The combination mimics the body's natural overnight GH secretion pattern: sharp peaks followed by sustained elevation, then a clean return to baseline before the next pulse. This article covers exactly how those pharmacokinetics translate into dosing protocols, what reconstitution and storage timelines preserve peptide integrity, and what preparation errors negate bioavailability entirely.

How CJC-1295 No DAC & Ipamorelin Work Differently From DAC Variants

CJC-1295 no DAC is Modified GRF 1-29. A truncated 29-amino-acid analogue of growth hormone-releasing hormone (GHRH) that binds to GHRH receptors on anterior pituitary somatotrophs. Without drug affinity complex (DAC) modification, it remains unbound to serum albumin, allowing rapid clearance. Peak plasma concentration occurs at 15–20 minutes, half-life is 30 minutes, and measurable GH elevation returns to baseline within 90–120 minutes.

Ipamorelin is a ghrelin mimetic. It binds to ghrelin receptors (GHS-R1a) on the same somatotroph cells, triggering GH release through a pathway independent of GHRH. Its half-life is approximately 2 hours, with sustained GH elevation lasting 3–4 hours before clearance. Because it doesn't stimulate ACTH or cortisol release (unlike GHRP-2 or GHRP-6), it produces clean GH pulses without adrenal activation.

The DAC-modified version of CJC-1295 (often mislabelled as 'CJC-1295 with DAC') has a half-life of 6–8 days due to albumin binding, creating chronically elevated GH levels rather than pulsatile secretion. Research in endocrinology models shows that sustained GH elevation without normal troughs can lead to receptor desensitisation, blunted response over time, and suppression of natural pulsatile secretion. Modified GRF 1-29 avoids this by respecting the body's circadian GH architecture. Sharp pulses during deep sleep and post-exercise recovery, followed by baseline periods that preserve receptor sensitivity.

Reconstitution & Storage Timelines That Preserve Peptide Integrity

Lyophilised CJC-1295 no DAC and ipamorelin must be stored at −20°C before reconstitution. Once mixed with bacteriostatic water (0.9% benzyl alcohol), both peptides are stable at 2–8°C for 28 days. Temperature excursions above 8°C. Even for 30–60 minutes during shipping or handling. Cause irreversible conformational changes to the peptide backbone. Neither visual inspection nor at-home potency testing can detect this denaturation.

Reconstitution protocol: inject bacteriostatic water slowly along the inside wall of the vial, allowing it to run down the glass rather than spraying directly onto the lyophilised cake. The peptide will dissolve passively within 60–90 seconds without agitation. Shaking or vigorous swirling shears peptide bonds, reducing bioavailability by 15–40% based on stability studies of similar modified GHRH analogues.

Post-reconstitution storage requires consistent refrigeration. Every freeze-thaw cycle reduces potency by approximately 10–20%. If travelling, purpose-built peptide coolers (like FRIO insulin wallets) maintain 2–8°C for 36–48 hours using evaporative cooling without electricity. Standard ice packs risk freezing reconstituted peptides, which denatures them just as effectively as heat exposure.

Our Real Peptides team ships lyophilised peptides with temperature-logging cold packs and includes reconstitution instructions with every vial. We've found that most degradation happens during the 72-hour window between mixing and first use. Not during long-term storage.

Dosing Windows & Stacking Protocols for Synergistic GH Pulses

Optimal dosing for CJC-1295 no DAC ranges from 100–200 mcg per injection, administered 1–3 times daily. Ipamorelin is dosed at 200–300 mcg per injection, matched to the same frequency. The two are almost always co-administered in the same syringe to maximise synergy: CJC amplifies pulse amplitude, ipamorelin extends duration.

Timing matters more than dosage volume. GH pulses naturally occur during deep sleep (stages 3–4 NREM) and immediately post-exercise. Administering the stack 30–60 minutes before sleep aligns with endogenous nocturnal secretion, compounding the effect. A second dose can be administered upon waking or immediately post-training to amplify exercise-induced GH release.

Critical spacing rule: doses should be separated by at least 4–6 hours. Administering a second injection before the first pulse resolves (within 3 hours) creates overlapping GH elevation without additional amplitude. Essentially wasting the second dose. The body's somatotroph cells require a refractory period to replenish releasable GH stores.

Researchers often pair CJC-1295 no DAC and ipamorelin with compounds like GHRP 2 or MK 677 in metabolic research models. MK-677 (ibutamoren) is an oral ghrelin mimetic with a 24-hour half-life. It maintains baseline GH elevation between injected pulses, creating a hybrid protocol that combines pulsatile peaks with sustained trough support.

CJC-1295 No DAC & Ipamorelin: Peptide Comparison

Peptide	Half-Life	Peak GH Release	Duration of Elevation	Primary Mechanism	Dosing Frequency	Professional Assessment
CJC-1295 No DAC (Modified GRF 1-29)	30 minutes	15–20 minutes	90–120 minutes	GHRH receptor agonist. Amplifies GH pulse amplitude	1–3x daily	Ideal for pulsatile protocols that mimic natural circadian GH secretion without receptor desensitisation
Ipamorelin	2 hours	30–45 minutes	3–4 hours	Ghrelin receptor agonist. Extends GH pulse duration without cortisol/ACTH release	1–3x daily	Clean GH release with minimal off-target effects; synergises with GHRH analogues for peak amplitude + duration
CJC-1295 With DAC	6–8 days	24–48 hours	7–14 days	GHRH receptor agonist with albumin binding. Creates sustained elevation	1x weekly	Long half-life risks receptor desensitisation and suppression of endogenous pulsatile GH secretion over time
GHRP-2	20–30 minutes	15–30 minutes	60–90 minutes	Ghrelin receptor agonist. Strong GH release with mild cortisol/prolactin elevation	2–3x daily	Potent but less selective than ipamorelin; useful in research models requiring robust GH stimulation
MK-677 (Ibutamoren)	24 hours	60–90 minutes	24+ hours	Oral ghrelin mimetic. Sustained GH and IGF-1 elevation	1x daily	Elevates baseline GH between injected pulses; pairs well with short-acting peptides for hybrid protocols

What If: CJC-1295 No DAC & Ipamorelin Scenarios

What If I Accidentally Left Reconstituted Peptides Out of the Fridge Overnight?

Discard the vial. Reconstituted peptides exposed to temperatures above 8°C for more than 2–3 hours undergo irreversible conformational changes to the peptide backbone. The solution may still appear clear, but bioavailability is compromised. Injecting denatured peptide wastes the dose and skews research data. Lyophilised (unmixed) peptides can tolerate brief ambient exposure (24–48 hours at 20–25°C), but once reconstituted, cold chain integrity is non-negotiable.

What If I Mix CJC-1295 No DAC and Ipamorelin in the Same Syringe?

This is standard practice and actively recommended. Both peptides are reconstituted in bacteriostatic water at neutral pH, making them chemically compatible when drawn into the same syringe. Co-administration ensures simultaneous GHRH receptor and ghrelin receptor activation, maximising synergistic GH release. Draw ipamorelin first (higher volume), then CJC-1295 no DAC. Total injection volume typically ranges from 0.3–0.5 mL subcutaneously.

What If I Want to Dose Only Once Daily Instead of Multiple Times?

Single daily dosing is viable but suboptimal for replicating natural pulsatile GH secretion. Administering the stack 30–60 minutes before sleep captures the body's primary nocturnal GH pulse, which accounts for 60–70% of daily GH output. A second morning or post-training dose amplifies exercise-induced pulses, compounding metabolic and recovery effects. Research models using single daily dosing show measurable results, but twice-daily protocols consistently demonstrate greater IGF-1 elevation and fat oxidation markers.

What If the Lyophilised Powder Looks Clumped or Discoloured Before Reconstitution?

Lyophilised peptides should appear as a uniform white or off-white cake. Discolouration (yellow, brown, or grey tint) or excessive clumping suggests oxidative degradation, likely from improper storage or manufacturing contamination. Do not reconstitute. Contact the supplier for replacement. High-purity peptides from regulated 503B facilities like those offered by Real Peptides undergo third-party purity verification (≥98% via HPLC) and include certificates of analysis with every batch.

The Clinical Truth About CJC-1295 No DAC Half-Life Expectations

Here's the honest answer: researchers new to peptide protocols often assume longer half-lives equate to better efficacy. That's backwards for growth hormone secretagogues. The 30-minute half-life of CJC-1295 no DAC and the 2-hour duration of ipamorelin aren't limitations. They're the mechanism that preserves physiological GH architecture.

Chronic GH elevation from long-acting analogues (like DAC-modified CJC or synthetic GH itself) suppresses the body's natural pulsatile secretion over time. Somatotroph cells downregulate GHRH and ghrelin receptors when constantly stimulated, blunting response and reducing endogenous GH production. Modified GRF 1-29 avoids this by creating sharp, transient pulses followed by clean baseline periods. Exactly how the body regulates GH during deep sleep and recovery.

The short half-life also reduces off-target effects. Sustained GH elevation increases IGF-1 chronically, which research links to insulin resistance, joint oedema, and carpal tunnel symptoms in long-term models. Pulsatile protocols using CJC-1295 no DAC and ipamorelin elevate IGF-1 within physiological ranges (200–300 ng/mL in human equivalent studies) without the supraphysiological spikes that cause these adverse events.

Most peptide protocols fail not at the injection stage but during the reconstitution and storage window. A single temperature excursion during shipping, a freeze-thaw cycle, or agitation during mixing denatures the peptide irreversibly. Visual clarity means nothing. Denatured peptides remain transparent but lose biological activity entirely.

The most common mistake we see is dosing CJC-1295 no DAC once weekly because researchers confuse it with the DAC variant. Modified GRF 1-29 requires multiple daily doses to sustain pulsatile GH secretion. Weekly dosing wastes the compound. By the time you inject again, seven days of potential pulses have passed with zero GH amplification. If your protocol involves weekly injections, you're using the wrong peptide.

For researchers exploring synergistic approaches, pairing CJC-1295 no DAC and ipamorelin with metabolic support compounds can enhance measurable outcomes. Our FAT Loss Stack and Body Recomp Bundle combine peptides with complementary mechanisms. GH secretagogues paired with mitochondrial activators and insulin sensitisers. To model the full cascade of metabolic effects rather than isolating GH alone.

CJC-1295 no DAC's 30-minute half-life isn't a weakness. It's proof the peptide was designed to work with the body's endocrine system, not override it. Respect the pharmacokinetics, and the results follow. Ignore them, and you're running an expensive saline protocol.

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

CJC-1295 no DAC (Modified GRF 1-29) has a plasma half-life of approximately 30 minutes, with peak GH release occurring at 15–20 minutes post-injection. Measurable GH elevation returns to baseline within 90–120 minutes, creating a transient pulse rather than sustained elevation. This short duration preserves the body's natural pulsatile GH secretion pattern and prevents receptor desensitisation that occurs with longer-acting analogues.

No. Once reconstituted with bacteriostatic water, both peptides must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C — even for 30–60 minutes — cause irreversible conformational changes to the peptide backbone, rendering them biologically inactive. Lyophilised (unmixed) peptides can tolerate brief ambient exposure (24–48 hours at 20–25°C), but reconstituted solutions require strict cold chain management.

CJC-1295 no DAC (Modified GRF 1-29) has a 30-minute half-life and creates pulsatile GH release, while CJC-1295 with DAC has a 6–8 day half-life due to albumin binding, producing sustained GH elevation. The DAC variant risks receptor desensitisation and suppression of endogenous GH secretion over time. Modified GRF 1-29 respects the body's natural circadian GH architecture — sharp pulses during sleep and recovery followed by baseline periods that preserve receptor sensitivity.

Optimal protocols use 1–3 doses per day, spaced at least 4–6 hours apart. The most common regimen is twice daily: 30–60 minutes before sleep to align with nocturnal GH secretion, and either upon waking or immediately post-training to amplify exercise-induced pulses. Single daily dosing is viable but suboptimal — research models using twice-daily protocols show greater IGF-1 elevation and metabolic effects compared to once-daily administration.

Yes. Because CJC-1295 no DAC and ipamorelin create pulsatile GH release without suppressing endogenous production, discontinuation allows natural GH secretion to resume immediately. This contrasts with long-acting GH analogues or synthetic GH, which can suppress the hypothalamic-pituitary axis and require weeks to months of recovery. The short half-lives of Modified GRF 1-29 and ipamorelin preserve physiological GH architecture rather than replacing it.

Administering a second dose before the first GH pulse resolves creates overlapping elevation without additional amplitude — essentially wasting the second injection. Somatotroph cells require a 4–6 hour refractory period to replenish releasable GH stores after stimulation. Dosing too frequently reduces peak pulse height and blunts overall response, negating the synergistic benefit of the GHRH + ghrelin receptor co-activation mechanism.

You can't tell visually. Denatured peptides remain clear and transparent — neither appearance nor home testing can detect conformational damage to the peptide backbone. The only reliable indicators are storage history (temperature logs, freeze-thaw cycles) and measurable outcomes in controlled research models. This is why strict adherence to reconstitution protocols, refrigeration at 2–8°C, and use within 28 days post-mixing are non-negotiable for maintaining bioavailability.

Yes. Researchers often stack these peptides with compounds like GHRP-2, MK-677 (ibutamoren), or metabolic modulators in multi-pathway protocols. MK-677 is particularly synergistic: its 24-hour half-life maintains baseline GH elevation between injected pulses, creating a hybrid model that combines pulsatile peaks (from CJC + ipamorelin) with sustained trough support (from ibutamoren). Always verify peptide compatibility and pH stability when co-administering multiple compounds.

Ipamorelin is a ghrelin mimetic that binds to GHS-R1a receptors with slower dissociation kinetics than Modified GRF 1-29 binding to GHRH receptors. Its 2-hour half-life allows sustained GH elevation for 3–4 hours, extending the duration of each pulse. CJC-1295 no DAC's 30-minute half-life creates rapid, high-amplitude spikes. The combination synergises: CJC amplifies how high the GH pulse goes, ipamorelin extends how long it stays elevated — replicating the body's natural overnight GH secretion pattern.

Standard reconstitution is 2 mL bacteriostatic water per 2 mg peptide vial, yielding 1 mg/mL concentration. Inject the water slowly along the inside wall of the vial — do not spray directly onto the lyophilised cake. The peptide dissolves passively within 60–90 seconds without agitation. Shaking or vigorous swirling shears peptide bonds and reduces bioavailability by 15–40% based on stability studies of modified GHRH analogues. Reconstituted solutions remain stable at 2–8°C for 28 days.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA